A potentially revolutionary clinical trial using magic mushrooms to treat depression is being held up by ‘absurd’ British and European laws which restrict the use of illegal drugs in research.
Following previous experiments which found the psychotropic substance in magic mushrooms helped allay signs of depression in people who had failed to respond to other treatments, the British Medical Research Council awarded David Nutt and his team at Imperial College London an $844,000 grant to conduct a full clinical trial.
For the trial, 60 patients who had otherwise failed to react to at least two other forms of treatment would be administered a synthetically-manufactured form of psilocybin – the naturally occurring compound in some 200 species of mushrooms.
The problem: psilocybin is considered a Class A drug in the UK, meaning it is designated as having a high potential for abuse and no recognized medical use.
“The trial hasn’t started yet because the big problem is getting hold of the drug. We’re not allowed to go and pick the mushrooms anymore and finding a company to provide this illegal drug in a way that can be prepared for trial use as yet has proved impossible,” Nutt said on the eve of the British Neuroscience Association’s Festival of Neuroscience in London.
“We are between a rock and a hard place, and that’s very unfortunate because if this is an effective treatment, as it may well be for some people, then they are obviously being denied that possibility.”Under British law, academic researchers are not allowed to manufacture their own Class A drugs and are therefore forced to obtain them from outside sources.
Companies must clear stringent regulatory hurdles to obtain the necessary license to supply the drugs. The process can take up to a year and triple the cost, the professor maintained.
Restrictive EU guidelines on Good Manufacturing Practice further impose strict stands for potential suppliers.
“We live in a world of insanity in terms of regulating drugs,” Reuters cites him as telling the neuroscience conference on Sunday.
“The whole field is so bogged down by these intransigent regulations, so that even if you have a good idea, you may never get it into the clinic.”
Saying that a group in Colombia unhindered “by the baggage of drug laws” and “drug controls” might beat his team to the punch, Nutt insisted that even a successful trial would not clear the way for medicinal psilocybin.
The Latest Bing News on:
Magic mushrooms to treat depression
- Microdosing Magic Mushrooms: Here's What the Health Experts Have to Sayon April 26, 2024 at 3:31 pm
Davis explains a person who takes magic mushrooms may experience side effects such as hallucination, impaired thinking, fear, agitation or confusion. These side effects are more likely if microdosing ...
- Magic mushrooms may help ease depression, but are they safe?on April 25, 2024 at 2:44 pm
The potential of magic mushrooms to act as a 'magic' solution to treat depression is getting a lot of attention. One of the most important aspects is safety.
- UGA researchers explore whether magic mushrooms pose risk when treating depressionon April 25, 2024 at 10:48 am
Researchers agree that so-called “magic mushrooms” are an effective treatment for medication-resistant depression. However, to date, research hasn’t focused as much on the safety of psychedelic ...
- Side effects of 'magic mushrooms' similar to regular antidepressantson April 24, 2024 at 7:51 am
People in a new study who took psilocybin often experienced headache, nausea, anxiety, dizziness and elevated blood pressure -- side effects similar to those seen with regular antidepressants.
- Trying 'Magic Mushroom' Drug to Ease Depression? It Has Side Effectson April 24, 2024 at 12:54 am
Many people with tough-to-treat depression may be trying psilocybin, the active ingredient in magic mushrooms, as an alternative to antidepressants. Thinking that it's a "natural" drug ...
- Trying 'Magic Mushroom' Drug to Ease Depression? It Has Side Effectson April 23, 2024 at 5:00 pm
WEDNESDAY, April 24, 2024 (HealthDay News) -- Many people with tough-to-treat depression may be trying psilocybin, the active ingredient in magic mushrooms, as an alternative to antidepressants.
- Psilocybin Shows Promise for Treatment-Resistant Depression – But Is It Safe?on April 23, 2024 at 5:00 pm
Commonly referred to as “magic mushrooms,” psilocybin is a promising alternative treatment for people with medication-resistant depression and anxiety. Previous studies have suggested that the ...
- Magic mushrooms can treat medication-resistant depression—but are they safe?on April 23, 2024 at 9:23 am
New research suggests psilocybin has similar side effects to traditional antidepressants. Commonly referred to as "magic mushrooms," psilocybin is a promising alternative treatment for people with ...
- I tried psychedelic drugs to treat my depression. Here’s what happenedon April 11, 2024 at 10:01 am
There is a growing body of evidence that the psychedelic properties of magic mushrooms ... and depression. But other than through clinical trials there are few ways to access the treatment ...
- Magic mushrooms compound ‘effective at treating depression in cancer patients’on May 30, 2023 at 4:05 am
The psychedelic compound found in magic mushrooms has been found to ... currently assessing the efficacy of psilocybin in treatment-resistant depression in a Phase III trial.
The Latest Google Headlines on:
Magic mushrooms to treat depression
[google_news title=”” keyword=”magic mushrooms to treat depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
[/vc_column_text]
The Latest Bing News on:
Drug laws hampering research
- Food Testing Services Market Valuation Expected to Reach US$ 49.06 Billion by 2033: A Comprehensive Analysis of Growth Trendson April 19, 2024 at 8:17 am
The latest update of the Food Testing Services Market is estimated to grow at US$ 49.06 Billion by 2033 | | Future Market Insights ...
- FTC Urged to Take Decisive Action against Microsoft’s AI Dominanceon April 18, 2024 at 5:12 am
As FTC’s power expands, the possibility of having such authority to regulate the end of Microsoft’s AI or at least limit its domination in the cloud computing sector is becoming a reality. Currently, ...
- Scaffolding Market Size Projected to Surge $90.48 Billion Growth by 2033, Exhibit a CAGR of 5.36%on April 16, 2024 at 6:00 pm
Scaffolding market size is anticipated to grow from USD 53.68 Billion to USD 90.48 Billion in 10 years: In developing countries like China, India, and Brazil, the need for safe, high-quality ...
- Nigeria: Why Farmers Should Ignore Deceit On GM Crops - Rose Gidadoon April 15, 2024 at 6:10 am
Dr Rose Gidado is a director, Agricultural Biotechnology Department at the National Biotechnology Development Agency. She has a long history in the biotech industry, having held positions, including ...
- The Mexican Embassy Raid in Ecuador Will Backfire for Noboaon April 8, 2024 at 5:40 am
Latin America should have a regional conversation about how its corrupt politicians abuse the asylum system by seeking refuge in foreign embassies to avoid accountability for their crimes. But that ...
The Latest Google Headlines on:
Drug laws hampering research
[google_news title=”” keyword=”drug laws hampering research” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
1 Comments
RC Gliders
neurogenesis,,,we share same intricate pathways in our brain chemistry as do mushrooms, its a no trainer, thank you for the article, one day this class A shenanigans hopefully will be released